SUPN: Supernus Pharmaceuticals, Inc. is a Buy
The current rating for SUPN is 70, which is
its historic median rating of 50. This indicates lower risk than normal.
The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.